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1. Introduction
Type 1 diabetes (T1D) is one of the most common chronic diseases in developed countries
and represents about 10% of all cases of diabetes. It is caused by a selective destruction of
insulin-producing β cells in the pancreas. The disease has two subtypes: 1A, which includes
the common, immune-mediated forms of the disease; and 1B, which includes nonimmune
forms. In this review, we focus on subtype 1A, which for simplicity will be referred to as
type 1 diabetes. [81, 34]. An increasing incidence rate of T1D has been observed for the last
few decades especially in young individuals (less than five years old) [163]. The cause of
T1D is still unknown. Several factors interact and lead to the development of the disease. An
inflammatory islet infiltrate (insulitis) can be observed at the symptomatic onset of T1D, and
reflects the immune response to β-cells [45]. T1D is an autoimmune disease, which implies a
role of immune response effectors in the pathogenic processes and a failure of tolerance to‐
wards β-cell antigens.The susceptibility to T1D is influenced by genetic factors. More than
20 loci in addition to those located in the human leukocyte antigen (HLA) class II locus (es‐
pecially DQ and DR) on chromosome 6 are involved. Another contribution to the pathogen‐
esis of the disease could rely on epigenetic modifications (such as DNA methylation) and
parent-of-origin effects [11]. Genetic modifications in the population cannot explain the rap‐
idly increased incidence of T1D in most populations. Altogether, the incidence variation
from one season to another, the relationship between immigration and disease develop‐
ment, and the differences in incidence in different parts of the world in neighboring popula‐
tions with similar genetic profiles, suggest that the disease is a result of interaction of genetic
and environmental factors [94].
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Interplay between immune response, genetic and environmental factors such as nutriments,
drugs, toxin and viruses play a role in the pathogenesis of the disease. Several teams paid
attention to the relationship between viruses and type 1 diabetes, and their role in the patho‐
genesis of the disease. A novel subtype of type 1 diabetes called fulminant type 1 diabetes,
without evidence of autoimmunity has been observed [61]. In that disease the role of viruses
is strongly suspected as well, but is out of the scope of this chapter.
The relationship between type 1 diabetes in human beings and animals and various viruses
belonging to different families has been investigated. Enteroviruses are among the viruses
most able to be involved in the pathogenesis of autoimmune type 1diabetes.
After a presentation of the role of various viruses in the disease we will focus on enteroviruses,
and then the clinical studies that were conducted to assess the relationship between enterovi‐
ruses and autoimmune T1D will be detailled. Thereafter the results of experimental investiga‐
tions aimed to elucidate the link between these viruses and the disease will be analyzed.
2. Various viruses have been associated with the development of type 1
diabetes
The role of viral infections in the pathogenesis of T1D has long been suspected and several
viruses have been associated with T1D in various studies [160, 162]. In humans, observa‐
tions of acute diabetes succeeding to destruction of β-cells by cytopathic effect of viral infec‐
tion remain exceptional. Some viruses, as mumps, influenza B virus or human herpes virus
6 have already been reported in cases of acute T1D. Nevertheless, the fact that T1D devel‐
oped after the infection by such commun viruses suggest that factors within the host play
more important roles than virus itself in the etiology of T1D [27, 59, 126].
The relationship between viral infection and T1D is mainly based on epidemiological argu‐
ments. The incidence of many allergic and autoimmune diseases has increased in developed
countries (North-South gradient) over the past three decades, particularly in young chil‐
dren. Concomitantly, there was a clear decrease in the incidence of many infectious diseases
in these countries, probably explained by the introduction of antibiotics, vaccination, and an
improved hygiene and better socioeconomic conditions [6, 163].
Interestingly, viruses have been reported to be associated with T1D occurrence in animals.
Experimental animal models, as BioBreeding (BB)-rat, nonobese diabetic (NOD) mouse or
specific transgenic mouse strains, were used to investigate the mechanism by which viruses
can modulate diabetogenesis.
2.1. Viruses and human type 1 diabetes
2.1.1. Rubella
Several reports have shown that congenital rubella was associated with induction of islet au‐
toantibodies in 10% to 20% of cases of congenital rubella, within 5 to 25 years [18, 56, 71].
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The serum levels of antibodies against measles, mumps, and rubella (MMR) and autoanti‐
bodies against pancreas islet cells (ICA), islet cell surface, glutamic acid decarboxylase auto‐
antibodies (GADA), and insulin were determined in 386 school children between 11 and 13
years of age, before and 3 months after vaccination with combined MMR vaccine. It has
been shown that children with rubella antibodies before vaccination had higher levels of
ICA than seronegative children [98]. However, a study conducted in 2003 showed inconsis‐
tent results: in fact, no signs of β-cells autoimmunity (ie detection of ICA, insulin autoanti‐
bodies (IAA), antibodies to the tyrosine phosphatase related IA-2 molecule (IA-2 A) and
glutamic acid decarboxylase (GADA)) were detected in 37 subjects with congenital rubella
syndrome or exposed to rubella virus during fetal life [165]. The role of rubella in the trig‐
gering of T1D has been determined in hamsters. This study revealed that an autoimmune
process and diabetes developed after rubella virus infection in neonatal hamsters [121].
Some authors suggested the molecular mimicry as a mechanism for rubella virus causing
T1D, on the basis of co-recognition of β-cell protein determinants, such as GAD, and various
rubella peptides by T-cells [118]. Recently, a clinical study has confirmed a significant asso‐
ciation between type 1 diabetes incidence and rubella in children in Italia [120].
2.1.2. Rotavirus
Rotavirus (RV), the most common cause of childhood gastroenteritis, has been suspected to
trigger or exacerbate T1D in a few studies. Honeyman et al. showed a specific and highly
significant association between RV seroconversion and increases in autoantibodies. Serum
of 360 children with a parent or sibling with type 1 diabetes had been assayed for IAA, GA‐
DA, and IA-2A every 6 months from birth. In all children, 24 children had been classified as
high-risk children because they developed diabetes or had at least 2 islet antibodies or 1 islet
antibody detected on at least 2 occasions within the study period. In high-risk children, 86%
developed antibodies to IA-2, 62% developed insulin autoantibodies, and 50% developed
antibodies to GAD in association with first appearance or increase in RV IgG or IgA [70]. In
2002, Coulson et al demonstrated that rotavirus could infect pancreas in vivo [35]. In this
study, nonobese diabetic (NOD) mice were shown to be susceptible to rhesus rotavirus in‐
fection. Pancreatic islets from NOD mice, nonobese diabetes-resistant mice, fetal pigs, and
macaque monkeys supported various degrees of rotavirus growth. Human rotaviruses that
were propagated in African green monkey kidney epithelial (MA104) cells in the presence of
trypsin as previously described [128] replicated in monkey islets only [35]. In another study,
the effect of RV infection on diabetes development, once diabetes was established, was de‐
termined on NOD and NOD8.3 TCR (transgenic for a T-cell receptor (TCR)) mice. The de‐
gree of diabetes acceleration was related to the serum antibody titer to RV. Thus, rotavirus
infection aggravated insulitis and exacerbated diabetes, after β-cell autoimmunity was es‐
tablished [60]. Furthermore, rotavirus was also suspected to contain peptide sequences, in
VP7 (viral protein 7), highly similar to T-cell epitopes in the islet autoantigens GAD and ty‐
rosine phosphatase IA-2, suggesting that T-cells directed against RV could induce or ampli‐
fy islet autoimmunity by molecular mimicry, in children with genetic susceptibility.
Honeyman et al. also demonstrated that peptides in RV-VP7, similar to T-cell epitopes in
IA-2 and GAD65, bound strongly to HLA-DRB1*04. The proliferative responses of T-cells to
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rotavirus peptide and islet autoantigen-derived peptides were significantly correlated [72].
Altogether, these observations suggested that RV infection could trigger or exacerbate islet
autoimmunity by molecular mimicry.
2.1.3. Mumps
In 1992, Parkkonen et al showed that mumps virus was able to infect β-cells, leading to a
minor decrease in insulin secretion in human fetal islet cultures [119]. The infection was in‐
variably associated with an increase in the expression of human leucocyte antigen (HLA)
class I molecules, mediated by soluble factors secreted by infected T cells, which could exag‐
gerate the autoimmune process in pre-diabetic individuals by increasing the activity of au‐
toreactive cytotoxic T cells [119]. Moreover, ICA have been observed in 14 out of 30 sera of
children with mumps. In most children, the ICA persisted for no more than 2-4 months, al‐
though 2 children have been positive for 15 months. Nevertheless, no ICA-positive child ac‐
quired diabetic glucose metabolism, apart from one child who had persistent ICA and
acquired diabetes mellitus three weeks after mumps infection [62]. Since the introduction of
vaccination against MMR in most of occidental countries, several studies have reported on
the relation between vaccination at childhood and the development of T1D [41, 78, 79]. Hyo‐
ty et al. demonstrated that vaccination against MMR in Finland was followed by a plateau in
the rising incidence of T1D 6–8 years later suggesting a causal relation between these viral
infections and the development of T1D [79]. However, the incidence of T1D continued to
rise after the plateau. Other studies hypothesized that childhood vaccination would rather
promote the development of T1D. No evidence has been found for the triggering effect of
childhood vaccination on the development of T1D later in life [41, 78]. Hyoty et al. described
a shared epitope, a 7 amino acid-long sequence (YQQQGRL), in mumps virus nucleocapsid
and in MHC class II-associated invariant chain, which might cause immunological cross-re‐
activity between these molecules [80].
2.1.4. Human Endogenous Retroviruses
Human Endogenous Retroviruses (HERVs) are sequences which occupy about 10% of the
human genome and are thought to be derived from ancient viral infections of germ cells. In
some medical conditions, HERVs genes could be transcripted, expressed in protein and
could be responsible of the development of autoantibodies that might react against host pro‐
teins. As a result, these mechanisms could lead to autoimmune diseases, such as T1D.
HERVs may also dysregulate the immune response by being moved and inserted next to
certain genes involved in immune regulation whose expression would be consequentially
altered. Finally, HERVs are known to induce proinflammatory cytokines production, as
IL-1β, IL-6, or TNF-α, by cells, such as monocytes [10]. The HERV-K18 variant has been
shown to encode for a superantigen (SAg) that is recognized by T-cells with TCR Vβ7 chains
and causes dysregulation of the immune system. HERV-K18 mRNA has been found to be
enriched in tissues of patients with acute T1D. HERV-K18 transcription and SAg function in
cells capable of efficient presentation are induced by proinflammatory stimuli and may trig‐
ger progression of disease to insulitis or from insulitis to overt diabetes [101]. The HERV-
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K18 variant, which is transcriptionally silent, could be directly transactivated by EBV
(Epstein Barr Virus) or HHV-6 (human herpes virus 6), or alternatively through the EBV or
HHV-6- induced production of the IFN-α [143, 144].
Rubella virus, rotavirus, mumps virus and endogenous retroviruses are RNA viruses whose
role in type 1 diabetes has been suspected. In addition to RNA viruses, it has been reported
that DNA viruses as well could be involved in the development of the disease as described
in the following paragraphs.
2.1.5. Cytomegalovirus
In 1988, Numazaki et al showed that cytomegalovirus (CMV) was able to infect tissue mon‐
olayer cultures of human fetal islets [112]. CMV infection apparently did not cause direct
destruction of β-cells but was leading to changes in production of insulin [112]. Hille‐
brands et al. demonstrated that R(at)-CMV accelerated onset of diabetes without infecting
pancreatic islets in BB-rats and suggested that virus-induced recruitment of peritoneal mac‐
rophages to the pancreas triggered the accelerated development of insulitis by enhancing
activation of T-cells in pancreas [65]. In 2003, van der Werf et al indicated that R-CMV in‐
duced a very strong T-cell proliferative response in BB-rats suggesting that R-CMV might
directly activate autoreactive T-cells resulting in accelerated onset of diabetes [161]. In 2010,
Smelt et al demonstrated that RCMV induced a low, persistent infection in rat β-cells, as‐
sociated with an increasing β-cell immunogenicity, which might be an essential step in β-
cells destruction and in the development or the acceleration of the onset of T1D [137].
Concerning the role of Human CMV (HCMV) in diabetogenesis, [64] postulated that there
is T-cell cross-reactivity between Human CMV (HCMV) and GAD65 in pancreatic islet β-
cell. HCMV-derived epitope could be naturally processed by dendritic cells and recog‐
nized by GAD65 reactive T-cells. Thus, HCMV may be involved in the loss of T-cell tolerance
to autoantigen GAD65 by a mechanism of molecular mimicry leading to autoimmunity
[64]. In 2008, Aarnisalo et al analysed specific anti-CMV IgG antibodies in 169 serum sam‐
ples from children who had developed the first T1D-associated autoantibody by the age
of 2 years, and, in parallel, in 791 serum control from healthy children [1]. No associa‐
tion between perinatal CMV infection and progression to T1D was observed. This study con‐
cluded that perinatal CMV infections were not particularly associated with early serological
signs of beta cell autoimmunity or progression to T1D in children with diabetes risk-asso‐
ciated HLA genotype [1]. However, serological, immunological, histological signs of auto‐
immunity and allograft rejection appeared concomitantly with early CMV infections in one
type 1 diabetic patient receiving pancreas allograft. This observation suggests that persis‐
tent CMV infections might be relevant to the pathogenesis of type 1 diabetes [177].
2.1.6. Parvovirus B19
Several cases of autoimmune disease occurrence after an acute infection with parvovirus
B19 have been reported. Kasuga et al. reported a case of a young adult who developed new
onset T1D after an infection with parvovirus B19. Serum levels of B19 IgM and antibodies to
the diabetic autoantigen IA-2 were significantly elevated. The authors noted homology in
amino acid sequences between B19 and the extracellular domain of IA-2 [88, 113]. Munakata
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et al described the case of a 40-year-old Japanese woman, in which three autoimmune dis‐
eases occurred after acute parvovirus B19 infection: rheumatoid arthritis, T1D and
Graves’disease [106]. Some authors attempted to explain these observations. Parvovirus B19
is known to promote a T-cell-mediated lymphoproliferative response, through the presenta‐
tion by HLA class II antigen to CD4 cells and thus could theoretically generate T-cell-medi‐
ated autoimmunity [166]. Vigeant et al suggested that parvovirus B19 infection may lead to
chronic modulation of the autoimmune response in predisposed individuals [164].
Although correlations between T1D and the occurrence of a viral infection that precedes the
development of the autoimmune disease have been recognized, mechanisms by which vi‐
ruses activate diabetogenic processes are still elusive and difficult to prove in humans. Stud‐
ies of animal virus-induced T1D provide a lot of information concerning the possible role of
virus infections in the induction of TID.
2.2. Viruses and animal type 1 diabetes
2.2.1. Encephalomyocarditis virus
A number of studies provide clear evidence that encephalomyocarditis virus (EMCV), be‐
longing to the Cardiovirus genus of the Picornaviridae family, is able to induce very rapid
onset of diabetes in mice. Based upon this evidence, EMCV-induced diabetes model has
been proposed as a model of fulminant T1D [135]. Several studies determined the existence
of two main variants of EMCV: the nondiabetogenic variant EMC-B virus, and the diabeto‐
genic variant EMC-D virus. EMCV-D has preferential tropism for pancreatic β-cells and can
induce diabetes in selective mouse strains, such as DBA/2 [102]. Nucleotide sequence analy‐
sis showed that EMC-D virus (7829 bases) differs from EMC-B virus (7825 bases) by only 14
nucleotides: two deletions of 5 nucleotides, 1 base insertion, and 8 point mutations. Further
studies revealed that only the 776th amino acid, alanine (Ala-776), of the EMC virus poly‐
protein, located at position 152 of the major capsid protein VP1, is common to all diabeto‐
genic variants. In contrast, threonine in this position (Thr-776) is common to all
nondiabetogenic variants [176]. A single point mutation at nucleotide position 3155 or 3156
of the recombinant EMC viral genome, resulting in an amino acid change (Ala-776 in
Thr-776), leads to the gain or loss of viral diabetogenicity [84]. A three-dimensional molecu‐
lar modeling of the binding site of the EMC viral capsid protein VP1 revealed that the sur‐
face areas surrounding alanine (or glycine) at position 152 of the VP1 was more accessible,
thus increasing the availability of the binding sites for attachment to β-cell receptors, result‐
ing in viral infection and the development of diabetes [85]. Baek et al. showed that macro‐
phages, especially mac-2 positive macrophages, were rapidly recruited in pancreas at the
early stage of EMC-D virus infection, playing a central role in the process of pancreatic islets
destruction in SJL/J mice [8, 9]. Recently, Mc Cartney et al. found that melanoma differentia‐
tion associated gene-5 (MDA5), a sensor of viral RNA eliciting IFN-I responses, IFN-α, and
Toll-Like Receptor 3 (TLR3) were both required to prevent diabetes in mice infected with
EMCV-D. In Tlr3-/- mice, a diabetes occured due to impaired tpe 1 IFN responses and β cell
damage induced directly by virus, rather than autoimmune T cells. Mice lacking just 1 copy
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of Mda5 developed transient hyperglycemia when infected with EMCV-D. Thus, in the case
of EMCV-D which infects and damages directly the pancreatic β cells, optimal functioning
of viral sensors and type 1 IFN responses are required to prevent diabetes [102].
2.2.2. Kilham rat virus
Ellerman et al. demonstrated the ability of Kilham rat virus (KRV), an environmentally ubiq‐
uitous rat parvovirus, to precipitate autoimmune diabetes in BioBreeding Diabetes-Resistant
(BBDR) rats that were not susceptible to spontaneous diabetes [47]. Chung et al. showed the
important role of macrophages and macrophage-derived cytokines (IL-12, TNF-α, and
IL-1β) in the KRV-induced autoimmune diabetes in the BBDR rats [29]. As it had been previ‐
ously shown, KRV did not directly infect β-cells. Thus, Choung et al. investigated the proc‐
ess by which KRV induced autoimmune pancreatic cells destruction. They discovered that it
was rather due to a disrupted immune balance: Th1-like CD45RC+CD4+ and cytotoxic CD8+
T-cells were up-regulated whereas Th2-like CD45RC-CD4+ T-cells were down-regulated.
Thus, KRV might be responsible for the activation of autoreactive T cells that are cytotoxic
to beta cells, resulting in T cell-mediated autoimmune diabetes. In the same study, this
group demonstrated that KRV-induced autoimmune diabetes in BBDR rats was not due to
molecular mimicry [30]. Zipris et al. reported that infection by KRV or H-1, a close homo‐
logue virus of KRV, induced similar humoral and cellular immune responses in BBDR rats
and Wistar Furth (WF) rats. Nevertheless, only KRV induced a decrease in splenic
CD4+CD25+ T cells (regulatory T cells or Treg) able to suppress autoreactivity, in both rat
strains. KRV was able to induce diabetes in BBDR rats but not in WF rats. The disease was
associated with accumulation of non proliferating Treg in pancreatic lymph nodes. Together
these data suggest a virus- and rat strain- specific mechanism of KRV-induced diabetes in
genetically susceptible rats as BBDR rats, through an alteration of T cell regulation. It ap‐
pears that Treg are no longer able to inhibit autoreactive T cells activation [178]. It has also
been shown that proinflammatory cytokines IL-6 and IL-12p40 were producted by spleen
cells cultured in vitro in the presence of KRV in BBDR and WF rats. Ligation of TLR9 with
CpG DNA induced the same pattern of cytokine production. In response to both KRV and
CpG DNA, spleen cell populations enriched for B cells (CD45R+) secreted significantly more
IL-12p40 than populations enriched for non B-cells (CD45R-). KRV was also able to stimu‐
late Flt-3L bone marrow-derived dendritic cells (DCs) to produce IL-12p40 in vitro. More‐
over, genomic DNA isolated from KRV, which is a single-strand DNA, induced the
production of IL-12p40 in spleen cells from BBDR rats. Thus, the ligand within KRV that in‐
duces IL-12p40 secretion in spleen cells is viral DNA. Using appropriate inhibitors of TLR-
signaling pathways, Zipris et al. indicated that the cytokine production by splenic cells was
Protein Kinase R (PKR) and NF-κB dependent, whose activation leads to type I IFN produc‐
tion. KRV-induced secretion of IL-12p40 by BBDR spleen cells was inhibited by specific
TLR9 inhibitors, as iCpG, and by chloroquine, which is a known inhibitor of endosomal
acidification, essential step for the recruitment of TLR9 in the lysosomal compartment.
Moreover, genomic DNA isolated from KRV induced the production of IL-12p40 in Flt-3L-
induced DCs derived from wild-type BBDR rats but not TLR9-deficient mice. Finally, ad‐
ministration of chloroquine to virus-infected BBDR rats decreased the incidence of diabetes
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and decreased blood levels of IL-12p40. These data indicates that the TLR9 -signaling path‐
way is implicated in the KRV-induced innate immune activation and participates to the de‐
velopment of autoimmune diabetes in the BBDR rat [179, 13].
EMC and KRV are natural viral pathogens of rodent that brought a lot of information as far
as the virus–induced pathogenesis of T1D. The role of these viruses in the human T1D has
not been reported, however, the Ljungan virus is another rodent virus that has been suspect‐
ed to be involved in human type 1diabetes.
2.2.3. Ljungan virus and human parechoviruses
The Ljungan virus (LV) is a RNA virus discovered in Sweden in the mid-1990s in rodents
(Myodes glareolus; formerly Clethrionomys glareolus called “bank vole”). This virus be‐
longs to the Parechovirus genus within the Picornaviridae family. Niklasson et al. described
the occurrence of T1D in 67 wild bank voles after 1 month of captivity in laboratory: diabetic
animals showed clinic signs of diabetes (persistent hyperglycemia with weight loss, ketosis,
and hyperlipidemia) and specific β-cell destruction associated with signs of autoimmunity:
increased levels of autoantibodies to GAD65, IA-2, and insulin. The disease was correlated
with LV antibodies. Moreover, LV antigen was detected by immunocytochemistry in the is‐
lets of diabetic bank voles. In parallel, two groups of new onset diabetic children were stud‐
ied: the first group represented a total of 53 children which were diagnosed with T1D
between 1992 and 1995, and the second group was composed of 289 children with newly di‐
agnosed T1D between 1995 and 2000. The study showed increased levels of LV antibodies in
newly diagnosed T1D children indicating a possible zoonotic relationship between LV infec‐
tion and human T1D [109].
In addtion to type 1 diabetes, viruses could be involved in the development of type 2 diabe‐
tes. Indeed, Niklasson et al. demonstrated that a type 2 diabetes-like disease could be in‐
duced by LV in a CD-1 mouse model. Pregnant CD-1 mice were infected with LV and kept
under not stressful conditions. After weaning, puberty male mice were kept under stress (all
males in the same cage) or not (animals in individual cage). All male mice received glucose
(100 g/l) in the drinking water. Only animals infected in utero and kept under stress devel‐
oped diabetes. Thus, in these animals, viral infection in utero, in combination with stress in
adult life could induce diabetes in males [110]. In 2007, Blixt et al. investigated the functional
characteristics of pancreatic islets, isolated from female and male bank voles considered as
infected by LV. About 20% of all specimens were classified as glucose intolerance/diabetes
(GINT/D) following a glucose tolerance test. Of these animals the majority became diabetic
by 20 weeks of age, and GINT/D animals had increased serum insulin levels. Functional dif‐
ferences, concerning insulin content, capacity to synthesize (pro) insulin, secrete insulin and
metabolize glucose, were observed between normal and GINT/D animals as well as between
genders. The increased serum insulin level and the increased basal islet insulin secretion in
GINT/D animals suggests that the animals had developed a type 2 diabetes probably due to
LV infection associated with stress in laboratory [12].
Human parechoviruses, like LV, belong to the Parechovirus genus; they have also been im‐
plicated in the development of T1D in humans. In a recent nested case-control study, the
Type 1 Diabetes32
“Environmental Triggers of Type 1 Diabetes: The MIDIA study”, stool samples from 27 chil‐
dren who developed islet autoimmunity (repeatedly positive for two or three autoantibod‐
ies) and 53 children matched for age and community of residence (control group) were
analyzed for human parechovirus using a semi-quantitative real-time polymerase chain re‐
action every month from the 3rd to the 35th month. Sera of children were tested for autoan‐
tibodies against GAD, IA-2, and insulin every 3 months until the age of 1 year and every 12
months thereafter. There was no significant difference in the number of infection episodes
between the two groups. There was also no significant difference in the prevalence of hu‐
man parechovirus in stool samples throughout the study period, except in samples collected
3 months prior to seroconversion, in which 16/77 samples (20.8%) from cases had an infec‐
tion as opposed to 16/182 (8.8%) samples from controls (OR = 3.17, p = 0.022) [148].
Various viruses were reported to be associated with human T1D: rubella and mumps virus,
rotavirus, retrovirus, human parechovirus, cytomegalovirus and parvovirus B19 (table 1). In
addition, viruses were reported to be associated with animal T1D: EMCV, KRV and LV, the
role of which in human type 1 diabetes has also been studied (figure 2). Using animal mod‐
els, as BB-rats, NOD mice or specific transgenic mouse strains, studies suggested different
mechanisms by which viruses may be involved in the initiation or modulation of autoim‐
mune process. These models suggested that a direct infection of islets, responsible for the
release of autoantigens, could explain the activation of T-cells and the development of auto‐
immunity. Another hypothesis supported by some studies was the concept of molecular
mimicry between virus and β-cells: a normal immune response against a viral antigen
would become pathogenic for β cells due to the existence of structural homologies with the
pancreatic antigen. In addition to their possible role in the activation of β-cell-reactive T
cells, viruses can reduce the capacity of Treg cells to maintain tolerance. Together, these
studies suggest that viruses through diffent mechanisms may trigger T1D and/or may par‐
ticipate in the amplification of the autoimmune process. In addition to the viruses presented
in this section, the major candidates are enteroviruses. Therefore the rest of this review will
be focused on these viruses.
RNA virus DNA virus
Human type 1 diabetes Togaviridae
Rubella virus
Paramyxoviridae
Mumps virus
Picornaviridae
Parechovirus
Enterovirus
Reoviridae
Rotavirus
Retroviridae
HERVs
Herpesviridae
Cytomegalovirus
Parvoviridae
Parvovirus B19
Animal type 1 diabetes Encephalomyocarditis virus
Ljungan virus
Kilham rat virus
Table 1. Viruses involved in human and animal type 1 diabetes grouped according to their genome and their family
(in red).
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3. Presentation of enteroviruses
3.1. Classification of human enteroviruses
The Picornaviridae family consists of 9 genera: Erbovirus, Kobuvirus, Teschovirus, Aphtovi‐
rus, Cardiovirus Hepatovirus, Parechovirus, Enterovirus. Human pathogens are in the four
last-mentioned genera. Human enteroviruses were previously classified on the basis of sero‐
logic criteria into 64 serotypes distributed as: poliovirus (PV), coxsackievirus A (CV-A), cox‐
sackievirus B (CV-B), echovirus and other enteroviruses. The International Committee on
Taxonomy of Viruses (ICTV) proposed a classification based on their phylogenetic relations
encompassing 4 species, HEV-A, B, C, D, which include various serotypes (table 2). Recent‐
ly, the former human rhinovirus species have been moved to the Enterovirus genus.
Species
(number of serotypes)
Representatives
Human enteroviruses A (12) Human coxsackievirus A2-8, A10, A12, A14, A16
Human enterovirus 71
Human enteroviruses B (36) Human coxsackievirus A9
Human coxsackievirus B1-6
Human echovirus 1–7, 9, 11–21, 24–27, 29–33
Human enterovirus 69
Human enteroviruses C (11) Human polioviruses 1-3
Human coxsackieviruses A1, A11, A13, A15, A17–22, A24
Human enteroviruses D (2) Human enterovirus 68, 70
Human rhinoviruses A (75)
Human rhinoviruses B (25)
Human rhinoviruses C (48)
Unclassified enteroviruses (over 50)
Table 2. Classification of human enteroviruses, adapted from www.picornaviridae.com
3.2. Structure of enterovirus particles
Picornaviridae particles are small (30 nm), icosahedral, non-enveloped viruses with a single-
strand positive RNA genome (approxymatly 7 000- 8 500 nucleotides) (figure 1). The crystal
structure of diverses representatives of the family have been solved [69, 2]. The fundamental
capsid architecture is the same in all members of the family. The capsid is composed of 60
copies of each four structural proteins VP1 to VP4 in icosahedral symetry and protects the
single strand genomic RNA and associated viral proteins [138]. In each case, VP1, VP2 and
VP3 made of 240 to 290 residues (32.4-39.1 kDaltons) constitute the outer surface of the cap‐
sid. They are taking the form of eight-stranded antiparallel ß sheet structures with a “jelly
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roll” topology. In the case of enteroviruses and rhinoviruses, VP1 contains a cavity, or pock‐
et, accessible from a depression on the outer surface of the virus capsid. VP4 is a shorter pro‐
tein around 70 residues (7 kDaltons) lies across the inner face of the capsid with its N-
terminus close to the icosahedral fivefold axis and its C-terminal close to the threefold axis
[105]. The N-terminal residue of VP4 in all picornaviruses is covalently linked to the inner
surface of the capsid defining a channel through the inner and outer surfaces.
Figure 1. Organisation of the enterovirus genome, polyprotein processing cascade and architecture of enterovirus
capsid The genome of enteroviruses contains one single open reading frame flanked by a 5′-and 3’ untranslated re‐
gions (UTR). A small viral protein, VPg, is covalently linked to the 5′ UTR. The 3’UTR encoded poly(A) tail. The transla‐
tion of the genome results in a polyprotein which is cleaved into four structural proteins (dark gray) and seven non-
structural proteins (light gray and yellow). The sites of cleavage by viral proteinases are indicated by arrows. The four
structural proteins adopte an icosahedral symmetry with VP1, VP2 and VP3 located at the outer surface of the capsid
and VP4 at the inner surface. The single strand genomic RNA is located inside the capsid.
3.3. Viral proteins of enterovirus: synthesis and functions
All picornaviruses have a similar genome organization consisting of a molecule of approxi‐
mately 7,500 to 8,000 nucleotides (figure 1). The RNA genome is organized with one single
large open reading frame preceded by a long 5′-untranslated region (5’ UTR) [97]. It contains a
3’ poly(A) tail with a variable length from 65 to 100 nt. The virion RNA has a virus-encoded
peptide, VPg, covalently linked to the 5′ end of the viral genome. Translation of the RNA ge‐
nome yields a polyprotein of approximately 2,200 amino acids. An early cotranslational cleav‐
age of the polyprotein by the viral 2A protease (2Apro) releases a precursor protein P1 from the
N terminus of the polyprotein. The P1 protein contains all the capsid protein sequences. Sub‐
sequent cleavage of P1 by the viral 3CD protease (3CDpro) produces the capsid proteins VP1
and VP3 and the immature capsid protein VP0. Finally, the immature protein VP0 is cleaved to
VP4 and VP2. There is no known protease requirement for this cleavage. From the P2 region,
protein 2A may have an unidentified function in viral RNA synthesis. Protein 2B and its pre‐
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cursor 2BC have been suggested to be responsible for membranous alteration in infected cells.
From the P3 region, two precursors are synthesized: 3AB and 3BC. The precursor 3AB is a mul‐
tifunctional protein principally involved in the membrane association of replication complex.
Protein 3A is a membrane binding protein that plays a role in inhibiting cellular protein secre‐
tion. Protein 3B (VPg) is a small peptide containing 21 to 23 amino acids, which is covalently
linked with the 5’UTR. The precursor 3CD exhibits protease activity and is capable of process‐
ing the P1 precursor region. Protein 3C is the protease responsible for the majority of polypro‐
tein cleavages. Protein 3D has the RNA-dependent-RNA polymerase activity and is one of the
major components of the viral RNA replication complex.
3.4. Enterovirus lifecycle
The first stage of picornavirus infection of susceptible cells is mediated by the interactions of
viral capsid with specific receptor on the cell membrane (figure 2). Receptors used by differ‐
ent picornaviruses include members of the immunoglobulin-like family, the low density lip‐
oprotein receptor (LDLR) family (used by minor group of rhinovirus), the complement
control family (used by certain rhinovirus), the integrin family of cell adhesion molecules
(receptors for aphtovirus family) and the T cell immunoglobulin domain mucin-like domain
receptors (TIM-1), receptor for hepatitis A virus, [159].
Figure 2. Enterovirus lifecycle.
The group of immunoglobulin-like molecules includes several well characterized recep‐
tors for viruses of the enterovirus genus. For example, intercellular adhesion molecule-1
(ICAM-1) is the receptor for major group human rhinoviruses (HRVs), the Coxsackie and
adenovirus receptor (CAR), a component of the tight junction between cells in intact ep‐
ithelium, is the common receptor for Adenoviruses and Coxsakieviruses. These mole‐
cules are all type 1 membrane glycoproteins encompasing, for CAR, two extracellular
immunoglobulin-like (Ig-like) domains, a transmembrane domain, and a cytoplasmic do‐
main. The first Ig-like domain is responsible for virus binding. The interactions of the re‐
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ceptor with virus capsid induce conformationnal modifications of capsid proteins and
cellular receptor that initiate the process of viral entry and genome delivery to the cyto‐
plasm. In brief, receptor binding triggers capsid rearrangements that result in the external‐
ization of VP4 and the N-terminus of VP1. At the same time, released VP4 also interacts
with the membrane. VP1 and/or VP4 form a membrane pore through which the genom‐
ic RNA is transported into the cytoplasm [159.].
The enterovirus genome is a positive stranded RNA that can be used as messenger RNA
and immediately translated by the host cell to produce specific viral proteins. The viral ge‐
nomic RNA is then transcribed into a complementary negative RNA, which is used as a
template to synthezise new strands of genomic positive RNA. Enterovirus infection induces
vesicles in infected cell that are localized in the perinuclear region of the cell and are thought
to be the sites of RNA replication. These vesicles clusters where viral RNA can be detected
have been refered to as replication complexs (RCs). Viral RNA replication occurs at the sur‐
face of vesicles. RCs derive from cellular membranes participating to endoplasmic reticu‐
lum-to-golgi traffick, hijacked by viral proteins [19]. The viral protein 3A plays a role in the
formation of the RCs. Viral proteins synthesis and genomic RNA replication are catalyzed
by RNA-dependent RNA polymerase 3D and several other viral proteins, 2B, 2C and 3AB,
also participate in RNA replication [4]. It has been suggested that genome replication and
encapsidation are coupled [111]. To date, the VPg protein has been implicated as a determi‐
nant of encapsidation.The encapsidation of the RNA is associated to the processing of the
immature protein VP0 to yield VP4 and VP2. There is no known protease requirement for
this cleavage, and it is thought to be autocatalytic, depending only on the capsid proteins
themselves and perhaps the viral RNA. The cleavage of VP0 to form the virion is associated
with a significant increase in the stability of the particle [68]. It is commonly accepted that
enteroviruses exits the cell by lysis of the host cell. However, newly synthesized virus can be
detected long before lysis. In addition, enteroviruses are able to establish persitent infection
without killing the cell [32]. Both observations argue in favor of alternative exit pathways
probably with activation of the apototic program in enterovirus-infected cells. Enteroviruses
have a large distribution in the world. Fecal-oral route via the ingestion of contaminated wa‐
ter or food is the major way of enterovirus transmission. Enterovirus infections are generally
asymptomatic, but some of them, especially the one due to coxsackievirus B (CV-B), have
been associated with acute manifestations (around 20 diseases such as non-specific febrile
disease, cutaneous symptoms, meningitis, encephalitis, pericarditis etc.). In addition, their
role in chronic diseases, like chronic myocarditis, dilated cardiomyopathy, and T1D is
strongly suspected [81].
4. Relationship between enteroviruses and autoimmune type 1 diabetes:
clinical studies
Enterovirus infections are among the main environmental risk factors for autoimmune T1D
and they have been diagnosed more frequently in T1D patients than in healthy subjects. In
this section we report the different studies conducted to investigate the relationship between
Viruses and Type 1 Diabetes: Focus on the Enteroviruses
http://dx.doi.org/10.5772/52087
37
enteroviral infection and T1D. Theses studies have used different techniques to detect enter‐
oviruses or their components (RT-PCR, cell culture, immunohistochemistry, in situ hybridi‐
zation...) in blood (serum, plasma and leucocytes), stools, pancreas, intestine. Several studies
throughout the world have displayed a relationship between enterovirus infection and the
development of T1D (table 3).
We will present the detection of enteroviruses and/or their components in various biological
samples in patients with clinical type 1 diabetes first, and thereafter in patients with signs of
autoimmunity and/or risk of developing the disease.
4.1. Enterovirus in biological samples from patients with type 1 diabetes
4.1.1. Whole blood
The presence of enteroviral RNA in whole blood of adult patients with T1D has been report‐
ed by our group [5]. Viral RNA was detected by RT-PCR in 42% (5/12) of patients with new‐
ly diagnosed T1D (p <0.01 vs healthy subjects) and in 8% (1/12) of previously diagnosed T1D
patients suffering from metabolic ketosis decompensation (P=0.07 vs patients with newly di‐
agnosed T1D). RT-PCR was negative in the group of healthy subjects and patients with type
2 diabetes. Sequencing of amplified cDNA displayed that circulating enteroviral RNA in
these patients had strong homologies with CVB (CVB3 in 4 patients with newly diagnosed
T1D, CVB4 in another one, and in one previously diagnosed patient). This study demon‐
strated that enteroviral RNA could be detected in blood of adult patients at the onset or in
the course of T1D.
An other study, performed also by our group, encompassed 56 patients with T1D (25 chil‐
dren whose average age was 13 years and 31 adults with an average age of 37 years), and 37
control subjects divided into 2 groups: the first comprising 24 subjects without any infec‐
tious, immunological or metabolic disease, the second group includes 13 patients with T2D
[23]. The presence of IFN-α mRNA was detected by RT-PCR in whole blood of 42 out of 56
patients (75%) but in none of controls, and IFN-α was detected by a sensitive immunoassay
in serum of 39 out of 56 patients. Enteroviruses-RNA sequences were detected in 50%
(21/42) of patients with IFN-α in their blood, but not in patients without any IFN-α in their
blood. The detection of enteroviral RNA was positive in 25% (3/12) of children with newly
diagnosed T1D, 30% (4/13) of children with previously diagnosed T1D, 50% (10/20) of adult
patients with newly diagnosed T1D and 36% (4/11) of adult patients with previously diag‐
nosed T1D. Sequencing of amplified cDNA displayed that circulating enteroviral RNA in
these 21 patients had strong homologies with CVB (CVB3 in 8 patients; CVB4 in 8 patients;
CVB2 in 5 patients). The results of sequencing of circulating enteroviral RNA were concord‐
ant with the results of anti-CVB neutralizing antibodies assay. Otherwise, there was no sig‐
nificant relationship between enterovirus detection and age of patients or the pattern of
disease (metabolic decompensation or not)
In Sweden, blood spots are routinely taken on days 2-4 of life for analysis of inherited meta‐
bolic diseases in all newborns and are stored in a biobank. From this biobank, a Swedish
study investigated enteroviral RNA in blood spots from 600 children in the Swedish child‐
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hood diabetes register [39]. Six hundred healthy children were included as controls. Viral
RNA was found in 27 out of 600 (4.5%) diabetic children compared to 14 out of 600 (2.3%)
control children (p=0.04).
4.1.2. Serum and plasma
The polymerase chain reaction, targeting the 5’ non coding region of enteroviral RNA was
first used in an English study to detect viral genome in serum taken from 14 children at the
onset of T1D and 45 control children matched for age, sex, date of specimen receipt and, as
far as possible, geographic area [31]. In this study, a significant greater number of diabetic
children had positive PCR results compared with controls (64% vs. 4%). Sequencing of en‐
terovirus PCR products from six positive patients showed a significant homology with cox‐
sackie B3 and B4 viruses, and some common patterns were observed among the sequences
from infected diabetic children.
An English team investigated the relationship between enterovirus RNA and T1D in chil‐
dren  [108].  One  hundred  ten  children  (aged  0-15  years  with  an  average  of  7.1  years)
with newly diagnosed T1D were recruited.  Detection of  enterovirus RNA in serum col‐
lected  in  the  week  after  diagnosis  was  based  on  a  RT-PCR  amplifying  the  5’  noncod‐
ing region of enterovirus genome. Hundred and eighty-two control children were matched
to  cases  by  age  (average  age:  6.6  years),  sex  and  date  of  serum collection  at  the  same
hospital.  The  number  of  newly  diagnosed children  with  a  positive  RT-PCR was  signif‐
icantly  higher  than  in  the  control  group (27% versus  4.9%,  p  <0.005).  Moreover,  a  sig‐
nificant  proportion  of  diabetic  children  with  a  positive  RT-PCR  were  of  very  young
age.  Indeed,  enteroviruses  were  detected  in  37% (20/54)  of  T1D children  aged  under  7
years, whereas only 4.6% (5/111) of corresponding control children were positive for en‐
terovirus  RNA  (p  <0.005).  For  diabetic  children  older  than  7  years,  17.8%  (10/56)  were
found to  be  positive  for  enterovirus  RNA sequences,  while  viral  RNA was  detected  in
only  5.6%  (4/71)  of  corresponding  controls  (p  <0.05).
A French study evaluated the possible role of enteroviruses infections in the pathogenesis of
T1D (Coutant et al., 2002). Sixteen newly diagnosed T1D children were included in this
study. Forty nine control children matched for age, sex, date of venous collection and geo‐
graphic area. A highly sensitive RT-PCR was used to investigate RNA in serum from pa‐
tients and controls. Neutralzation antibodies to coxsackies viruses B1 to B6 were used to
characterize the positive PCR samples. Enterovirus RNA was detected by PCR in only 2 of
the 16 newly diagnosed T1D children and in only one of the 49 matched controls (p<0.1).
Neutralization assay could not detect antibodies against coxsackiesviruses B1 to B6.
Two hundred and six newly diagnosed T1D children and 160 controls were included in an
Australian study [37]. Enterovirus-RNA was found in either plasma or stool in 30% (62/206)
of newly diagnosed T1D but only in 4 % (6/160) of controls (p<0.001). Case patients, positive
for enterovirus RNA had lower C-peptide levels (p=0.04). Case children with enterovirus
RNA levels were more likely to have a severe diabetic ketoacidosis (p = 0.03). Enteroviruses
were detected in fewer children with HLA haplotype DRB1 * 03 DQB1 * 02 (p = 0.02) sug‐
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gesting that the likely role of enteroviruses in the development of diabetes is important in
some patients with specific genetic risk.
An Egyptian study included 70 diabetic children who were classified into 2 groups: the first
group (I), 40 patients with newly diagnosed diabetic patients (less than one year), the second
group (II), 30 children with diabetic patients with more than one year duration of disease
[100]. In the control group there were 30 normal healthy children. Enterovirus infection was
detected by viral culture of serum samples and confirmation of the results of tissue culture
isolation was done by RT-PCR. In addition, anti-CVB IgM and IgG antibodies were searched
by enzyme immuno assay. Enterovirus was isolated in group I (47.5%) and group II (23.3%).
Neutralization test revealed that most of cases were coxsackievirus B4. In this study, cox‐
sackievirus B IgM antibodies were significantly higher in diabetic patients of group I than
those in group II (p<0.01) but there was no significant difference between group I and group
II regarding IgG positivity.
A Japanese case-control study encompassed 61 patients with T1D aged 9 months to 40 years
and 58 non diabetic subjects aged 1 month to 40 years whose serum was collected the same
year [90]. A highly sensitive RT-PCR was used to investigate enterovirus RNA in serum
samples. Moreover, neutralizing antibodies against Coxsackievirus and antibodies to GAD
were measured and compared with the viral load and the enterovirus genotype. The detec‐
tion of enterovirus was positive in 23 out of 61 patients (37.7%) and in 2 out of 58 controls
(3.4%). The positivity of RT-PCR was decreasing by years gradually after the occurrence of
T1D, there was neither gender nor age tendency. The sequence analysis of PCR amplicons
displayed strong homologies with coxsackievirus B4 in 13 patients out of 23, and the level of
neutralizing anti-CVB4 antibodies was significantly high in positive patients in RT-PCR.
There was no relationship between the viral load in serum and antibodies against GAD.
A German group searched the enterovirus RNA by RT-PCR in the serum of diabetic chil‐
dren taken soon after the diagnosis of diabetes [104]. Seventeen out of 47 (36%) newly diag‐
nosed diabetic cases were positive for enteroviral RNA whereas 2 out of 50 control subjects
were positive (p<0.001).
Cuba is a country with a low incidence of T1D and with a high circulation of enteroviruses.
In a Cuban study, the frequency of enteroviral RNA detection by RT-PCR was significantly
higher in newly diagnosed T1D children whose diagnosis was made within 10 days before
inclusion [26.5% (9/34)] compared to controls [2.9% (2/68)], matched for age, gender, geo‐
graphic origin and date of serum collection (p = 0.0007) [127]. Enterovirus detection was
more likely associated with severe diabetic ketoacidosis at onset (pH <7.1, p = 0.03) and high
titres of autoantibodies against ICA (p <0.05).
4.1.3. Leucocytes and other biological samples
An English study included 17 newly diagnosed patients with T1D, 38 previously diagnosed
patients with T1D (the median duration of T1D was 4 years) and 43 age and sex matched
non-diabetic controls [53]. Enterovirus RNA was detected by PCR in peripheral blood mon‐
onuclear cells in 41 % of newly diagnosed patients with T1D, 39% of previously diagnosed
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patients and 31% of non diabetic controls. This study showed no difference between diabetic
patients and controls regarding the frequency of infection by enterovirus. Whether enterovi‐
ruses acted as non-specific agents with an abnormal immune response of the host, is a ques‐
tion raised by the authors of this study.
In a Swedish group, Yin and colleagues used RT-PCR to detect enterovirus RNA in PBMC
(peripheral blood mononuclear cells) from 24 newly diagnosed children patients [171]. The
24 control children were matched for age, sex and geographical location without evidence of
ongoing infection. RT-PCR was performed with primers (groups A and B) corresponding to
conserved areas in the 5'non-coding region. With group A primers, 50% (12/24) of newly di‐
agnosed patients had a positive enterovirus RT-PCR, however, control children were nega‐
tive (p<0.001). With group B primers, enterovirus sequences were detected in 46% (11/24) of
newly diagnosed patients, and in 29 % (7/24) of control children, but the difference was not
statistically significant. Taking into account the results obtained with the two sets of pri‐
mers, the detection of enterovirus RNA was positive in 75% (18/24) of newly diagnosed pa‐
tients and only in 29% (7/24) of control children.
One hundred and twelve diabetic children and 56 healty controls have been included in an
Italian study [154]. Enterovirus common capsid antigens were detected by immunofuores‐
cence in a panel of cell lines inoculated with total leucocytes from peripheral blood, and en‐
teroviral RNA was detected in these cultures as well. Enteroviruses were detected by RT-
PCR in 93/112 case children (83%) and 4/56 control children (7%), and directly in leukocytes
at lower frequency. Thirteen cases of familial enterovirus infection were observed.
Enteroviral RNA has been searched in PBMC, plasma, throat and stools of 10 newly diag‐
nosed children and 20 control children [132]. Viral RNA was found in PBMC of 4 patients
(40%), in plasma of 2 patients (20%), and in stools in 1 patient, in contrast, no sample was
positive in control children. All throat swabs from patients and controls were negative. Ac‐
cording to the authors, a prolonged enteroviral infection could be suspected in these pa‐
tients in front of a positive detection of viral RNA in PBMC and/or plasma together with a
negative detection of viral RNA in stool and throat swabs.
4.1.4. Pancreas
A 10 years old child with a flu-like illness within 3 days prior to admission in hospital for
diabetic ketoacidosis died on the 7th day of admission [175]. The autopsy showed infiltra‐
tion of the pancreas islets by lymphocytes with necrosis of beta cells. The inoculation of
mouse, monkey and human cell cultures with a homogenate of the patient's pancreas had
led to the isolation of a CVB4. Serology showed an 8 fold increase in titer of neutralizing an‐
tibody to this virus between the second hospital day and day of death. Inoculation of mice
with this viral isolate led to hyperglycemia, inflammation of the islets of Langerhans and ne‐
crosis of beta cells. Immunoflurescence detected viral antigen in beta cells of mouse pancre‐
atic section. The virus isolate obtained from this patient is known as CVB4 E2.
A few years later, a British group [52], did not find VP1 by immunohistochemistry in pan‐
creas beta cells of 88 patients who had died at clinical presentation of T1D. In contrast, by
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using the same method VP1 protein was found in cardiac myocytes from 12 of the 20 pa‐
tients whose cause of death was an acute coxsackievirus B myocarditis, and in seven of these
positive cases, insulitis was observed and VP1 was detected in islet endocrine cells, but rare‐
ly in exocrine pancreas. Together, these data suggested that the beta cell destruction in pa‐
tients with fatal diabetes was unlikely related to a direct cytopathic effect of coxsackievirus
B, however the role of viruses in the destruction of beta cells through an autoimmune mech‐
anism can not be excluded.
A few years later, another group investigated the presence of enteroviral RNA in the pan‐
creas of 2 children patients with fatal acute-onset T1D and 5 controls by using RT-PCR and
Southern blot hybridization [17]. The detection of Enteroviral RNA, and other viral genome
(cytomegalovirus, mumps and rubella) was negative in every case.
The relationship between enterovirus and T1D and the type of pancreatic cells infected with
enteroviruses has been invesigated by a finish group [172]. The study included 12 newborn
infants who died of fulminant infection with enteroviruses (myocarditis in most cases). Au‐
topsy pancreases from 65 patients with T1D and 40 control subjects matched for age and sex
were also studied for presence of enteroviral RNA by in situ hybridisation. Enteroviral RNA
was detected in pancreas of 58% (7/12) of the 12 newborns; the enterovirus-positive cells
were detected in numerous pancreatic islets and in some duct cells but not in exocrine pan‐
creas. In situ hybridisation identified enteroviruses in 6% (4/65) of diabetic patients. Entero‐
viral RNA was located exclusively in islets. None of the control subjects was positive for
enteroviral RNA.
More recently, an Italian team studied the relationship between enterovirus infection, in‐
flammation of pancreatic beta cells, autoimmunity and beta cell function [43]. Six newly di‐
agnosed T1D patients (1 week to 9 months) and 26 control organ donors were included in
this study. Immunohistochemistry, electron microscopy, RT-PCR and sequencing, and virus
isolation in cell culture were used to detect enteroviruses in pancreatic autopsic tissue. En‐
teroviral RNA was detected in 3 out of 6 diabetic patients but not in controls. Infection was
specific of beta cells with non-destructive insulitis and with naturel killer cell infiltration.
There was not apparent reduction of islet beta cells in these patients. The virus isolated from
one of these 3 patients, identified as CVB4 was able to infect human pancreatic beta cells of
nondiabetic multiorgan donors. Viral inclusions and signs of pyknosis were observed by
electronic microscopy, and a loss of beta cell function was assessed by insulin secretion re‐
sponse to glucose, arginine and glibenclamide. These data show that enterovirus could in‐
fect beta cells in patients with T1D and that these viruses could be responsible for
inflammation and functional abnormalities of these cells.
Recently, authors raised the issue of the relevance of pancreas tissue samples to display the
relationship between enterovirus infection and type 1diabetes, since no enteroviral RNA
was detected by RT-PCR in samples from pancreatic organ donors with diabetes [158]. Fur‐
ther investigation with pancreas from additionnal donors are needed to address the issue of
the persistence of enteroviruses in this organ. Whether enteroviruses are present in pancreas
tissue at the time of symptom onset should be investigated but tissue samples can not be
easily obtained by biopsy in the case of this organ.
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The prevalence of enteroviral capsid protein (VP1) in pancreatic autopsy tissue from 72
newly diagnosed T1D children and a large cohort of controls has been studied by immuno‐
histochemical staining by a british group [122]. The cell subtypes infected with enteroviruses
were identified by immunofluorescence. The criterion of positivity was the presence of at
least one intensely stained endocrine cell in an islet within any given section. According to
this criterion, 61% (44/72) of diabetic children were positive in immunohistochemistry ver‐
sus 7.7% (3/39) of control children (p <0.001). There was no significant difference regarding
age or gender between the VP1-positive and VP1-negative groups however the duration of
diabetes seemed to be lower in the VP1-positive group (2.32 months vs 16.5 months; p=0.06).
4.1.5. Stools
Entroviruses are present in stools of infected individuals [125]. The hypothesis of the role of
enteroviruses in T1D prompted researchers to look for these viruses in stools of patients.
An Italian group investigated enteroviruses in stools from 43 newly diagnosed diabetic chil‐
dren and 22 control children [42]. Stools and serum samples were collected within 2 months
from the beginning of diabetes symptoms. In order to isolate enterovirus, stools were inoculat‐
ed to cell cultures and in suckling mice. Neutralizing antibodies to coxsackie virus B4 and anti-
coxsackie viruses B1 to B6 complement fixing antibodies were measured. There was one case
with high antibodies against coxsackie B4 virus but no enterovirus was isolated from stools.
A 16 month-old child with a predisposing HLA group (B18 DRw3) developed diabetes [21].
The disease outcame at hospital on the third day of steroid therapy for febrile purpura with‐
in the week of diphtheria/pertussis/tetanus and polio vaccination. Coxsackievirus B5 was
isolated from stools and serologic studies showed a rise in titer of neutralizing antibodies
directed to that isolate from less than 10 on the first day to 640 on the eleventh day. The sud‐
den onset of T1D in the course an acute coxsackievirus B5 infection suggests the potential
involvement of this virus in the disease in that case.
4.1.6. Intestine
Different virological methods were used in a Finnish study to evaluate whether enterovirus‐
es can be found in small intestinal mucosa of 12 patients with T1D (age: 18 to 53, 2 out of
them were male) and 10 non-diabetic subjects (age 23 to 71, 3 out of them were male) [114].
These individuals underwent gastroscopy for gastrointestinal symptoms and intestinal mu‐
cosa biopsies were taken for morphological analysis, which did not reveal any abnormality.
To analyse the presence of enteroviruses in intestinal biopsy samples, immunohistochemis‐
try was used for detecting the viral protein VP1, and in situ hybridization. RT-PCR were
used for detecting viral RNA. Six out of 12 (50%) diabetic patients were positive for entero‐
viral RNA by in situ hybridization, whereas all control subjects were negative (p = 0.015).
Two of these positive patients had enteroviral RNA in the cells of lamina propria; four were
positive in the epithelial cells of villi, in the crypts and in the cells of lamina propria. Immu‐
nohistochemistry was positive in 9 out of 12 (75%) of diabetic patients but only in 10% (1/10)
of control subjects (p = 0.004): the protein VP1 was mainly localized in the epithelium. Viral
RNA was found by RT-PCR in a frozen sample from one of the 4 diabetic patients who were
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positive in both in situ hybridization and immunohistochemistry. There was no relationship
between the detection of enteroviral RNA in gut mucosa of diabetic patients and duration of
diabetes, gender, HLA type or hyperglycemia.
The discrepancy in results obtained by RT-PCR and in situ hybridization could be explained
by the fact that intestinal biopsy samples were obtained from two sites of the intestine, and
by differences in samples preparation. These results display that subjects with T1D have en‐
teroviral components in their gut mucosa.
4.2. Enterovirus in biological samples from individuals at high-risk of diabetes
A Finnish prospective study concerned children with prediabetic state, which were derived
from a previous study “Childhood Diabetes in Finland” (DiMe) [99]. The study investigated
enterovirus RNA in 93 serum samples from 11 prediabetic children who progressed to T1D
during the follow-up. One hundred and eight serum samples from 34 control children who
participated in the same cohort but did not develop autoimmunity against beta cells or T1D
were examined. In this study, serum samples from 47 children with newly diagnosed T1D
were also analysed. Antibodies against islet cells (ICA), glutamic acid decarboxylase (GA‐
DA), insulin (IAA) and the protein tyrosine phosphatase-related IA-2 protein (IA2-A) were
analysed. Antibodies against coxsackie viruses B1 to B6 were measured by neutralization as‐
say. Enterovirus RNA was found in 12 %( 11/93) of follow-up samples from prediabetic chil‐
dren compared to only 2% (2/108) of follow-up samples from matched controls (p<0.01).
Viral RNA was detected in none (0/47) of the serum samples obtained from diabetic chil‐
dren. The presence of enteroviral RNA was associated with a concomitant increase in ICA (p
<0.01) and GADA (p <0.05), whereas no increase was observed in the rates of IAA and
IA-2A. This study suggests that enterovirus genome can be found in serum of individuals
and that it is associated with the induction of autoimmunity several years before the onset of
symptoms. The presence of enterovirus RNA in serum of prediabetic children has been
studied in Cuba [127]. This study encompassed 32 children positive for antibodies against
ICA having a first-degree relative with T1D, 31 children, negative for antibodies against ICA
having a diabetic first-degree relative, and 194 controls, who were matched for age, gender,
geographic origin and date of serum collection. Enterovirus RNA was found in 15.6% (5/32)
of islet autoantibody-positive first-degree relatives children, whereas all controls were nega‐
tive for enteroviral genome (P = 0.003). Enterovirus RNA was found in 3.2% of 31 children,
negative for antibodies against ICA having a diabetic first-degree relative, and in 1.6% of
controls.
After seroconversion for islet antibodies (against GAD, insulin, IA-2), serum and rectal
swabs were collected every 3-6 months until diagnosis of diabetes in the Diabetes and Auto‐
immunity Study in the Young (DAISY) encompassing 2,365 american genetically predis‐
posed children for islet autoimmunity and T1D, according to HLA, and siblings or offspring
of people with T1D (regardless of their genotype) [141]. Fifty of the 140 children who sero‐
converted to positivity for islet autoantibodies progressed to T1D. The prevalence of entero‐
viral RNA in serum and rectal swabs as displayed by RT-PCR declined with age and
seemed to be higher at visits positive for multiple islet autoantibodies. The risk of progres‐
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sion to T1D following detection of enteroviral RNA in serum, in a 4-month interval, was sig‐
nificantly increased compared with negative detection. In contrast, the presence of
enteroviral RNA in rectal swabs did not predict progression to T1D, which is in agreement
with the results of the MIDIA study including 911 Norwegian children identified at birth
with a HLA genotype conferring a risk of T1D [149].
Thirty height children with an increased genetic susceptibility to diabetes followed-up from
birth who have progressed to T1D and 140 control children matched for sexe, date of birth,
hospital district and HLA-DQ-conferred genetic susceptibility to T1D were included in the
finnish type 1 Diabetes Prediction and Prevention study (DiPP) [115]. Serum samples were
analysed for enterovirus RNA by RT-PCR: 5.1% of samples were enterovirus RNA positive
in case children but only 1, 9% in control children (p<0. 01). In boys, the detection of entero‐
virus RNA during the 6 months preceding the discovery of autoantibodies was associated
with a risk of diabetes (p<0.01).
Biological
samples
Number
of Cases/
Controls
Children/
adults
patients
Positives
cases/
Controls
p value
Methods of
detection
Reference country
Whole blood 24/27 0/24 6/0
p <0.01
RT-PCR Andréoletti et al., 1997 France
Whole blood 56/37 25/31 21/0
p *
RT-PCR Chehadeh et al., 2000 France
Woole Blood 600/600 600/0 27/14
p=0.04
RT-PCR Dahlquist et al., 2004 Sweden
Serum 14/45 14/0 9/2
p*
RT-PCR Clements et al., 1995 England
Serum 110/182 110/0 30/9
p<0.005
RT-PCR Nairn et al., 1999 England
Serum 16/49 16/0 2/1
p>0.05
RT-PCR Coutant et al., 2002 France
Serum 70/30 70/0 26/0
p <0.05
Cell culture Maha et al., 2003 Egypt
Serum 61/58 NI 23/2
p<0.05
RT-PCR Kawashima et al., 2004 Japan
Serum 47/50 47/0 17/2
p<0.001
RT-PCR Moya-Suri et al., 2005 Germany
Serum 34/68 34/0 9/2
p=0.0007
RT-PCR Sarmiento et al., 2007 Cuba
Plasma
stools
206/160 206/0 62/6
plasma or stools
p<0.001
RT-PCR Craig et al., 2003 Australia
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Biological
samples
Number
of Cases/
Controls
Children/
adults
patients
Positives
cases/
Controls
p value
Methods of
detection
Reference country
PBMC 24/24 24/0 18/7
p*
RT-PCR Yin et al., 2002 Sweden
leucocytes 112/56 112/0 93/4
p*
RT-PCR Toniolo et al., 2010 Italy
PBMC
plasma
stools
throat
10/20
10/20
10/20
10/20
10/0 4/0 p>0.05
2/0
1/0
0/0
RT-PCR Schulte et al., 2010 Netherlands
Pancreas 149/21 NI 0/7
p*
IHC Foulis et al., 1990 England
Pancreas 65/40 0/65 4/0
p*
HIS Ylipaasto et al., 2004 Finland
Pancreas 6/26 2/4 3/0 IHC
Electronic
microscope
Cell culture
RT-PCR
Dotta et al., 2007 Italy
Pancreas 72/39 NI 44/3
p<0.001
IHC Richardson et al., 2009 England
Intestine 12/10 0/12 6/0
p=0.015
9/1
p=0.004
HIS
IHC
Oikarinen et al., 2007 Finland
Table 3. Detection of enterovirus and/or their components (RNA, proteins) in biological samples of patients with type
1 diabetes. PBMC: Peripheral Blood Mononuclear Cells, RT-PCR: Retrotranscription Polymerase Chain Reaction, IHC:
Immunohistochemistry, HIS: Hybridization in situ, NI: Not Indicated, p*: p value not mentioned.
5. Enterovirus and type 1 diabetes: Experimental approach
In previous sections of this review, clinical studies that were conducted to assess the rela‐
tionship between enteroviruses and T1D have been presented. A significant association be‐
tween enterovirus infection and T1D, particularly for studies that used molecular methods,
has been displayed, and when identified the most often involved enteroviruses were cox‐
sackieviruses B. Experimental studies have been performed to understand the possible link
between enterovirus and T1D. In the present section, the results of in vivo studies on one
hand and those of in vitro studies on the other hand are presented and analyzed.
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5.1. In vivo studies in animal models
In order to analyse the hypothesis that enterovirus infections enhance or elicit autoimmune
disorders such as T1D, a significant body of evidence is derived from investigations using
animal models. Most of them used to explore research hypotheses regarding the relation‐
ship between enteroviruses and type 1 diabetes are mouse models (NOD, C57BL/k,
C57BL/6, SJL/J, DBA/2, SWR/J, BALB/c, B10, CD-1…) [83]. Despite their limitation in diseas‐
es investigations, experimental models have greatly contributed to our knowledge of human
diseases. The predominance of murine models for the investigation of the relationship be‐
tween enteroviruses and T1D is due, among others, to a physiology relatively similar to that
of human beings and the presence of specific receptors, the more prominent of them could
be the coxsackievirus and adenovirus receptor (CAR) which is a receptor for coxsackievirus
B [86]. Therefore experimental datas have been obtained from models based on infection
with coxsackievirus B (CVB) (figure 3).
5.1.1. Enterovirus and immune system
Experimental in vivo studies have contributed improving our understanding of genetic and
immunological implications, enteroviral tropism and mechanisms of pancreatic β-cells de‐
struction in the context of enteroviral infection [83]. Enteroviruses generally infect the exo‐
crine pancreas, but some strains preferentially infect islets. Some studies have addressed the
role of CAR, the main receptor for CVB entry into host cell, in enteroviral tropism and target
organ infection. CAR is expressed by intestine, pancreas and heart epithelial cells, as well as
cardiomyocytes [54]. In transgenic mice CVB3 titers were markedly reduced in CAR-defi‐
cient tissues and pancreatic CAR deletion induced a strong attenuation of pancreatic CVB3
infection and pancreatitis [86].
The development of innate and adaptive immune responses is mediated by type I interfer‐
ons (IFNs) produced early during viral infection to induce an antiviral state within target
cells. Experimental studies have shown that mice deficient in type I IFNs receptor are more
susceptible and die more rapidly than controls when infected with CVB3 [169, 40]. An effi‐
cient immune response depends on rapid recognition of viruses by the innate immune sys‐
tem and this recognition is primarily achieved by pattern-recognition receptors such as toll-
like receptors (TLRs), retinoid-inducible gene 1-like receptors (RIG-1) and NOD-like
receptors. It is noteworthy that interactions between NOD-like receptors and enteroviruses
are still poorly understood.
Toll-like receptors are transmembrane glycoproteins expressed on the cytoplasmic mem‐
brane or in intracellular vesicals of several immune and non-immune cell populations; while
RIG-I-like receptors, represented by RIG-I and the interferon-induced with helicase C do‐
main 1 (IFIH-1), also called melanoma differentiation-associated gene 5 (MDA5) are ex‐
pressed in the cytosol of most cell types [91]. Among TLRs, TLR3, known to be double-
stranded RNA sensor on monocytes, is known to be crucial for the survival of mice infected
with CVB4 [123]; and the production of cytokines by murine plasmocytoid dendritic cells
have been shown to be closely linked with CVB detection and recognition by TLR7 [168].
The MDA5 is in turn essential for type I IFNs responses to CVB, since MDA5 knockout mice
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are deficient to type I IFN and are prone to early death when infected with CVB (Wang et
al., 2010). Thus, pattern-recognition receptors activation by enteroviruses results on IFNs
and chemokines production which could lead to an inflammatory state in infected tissues.
Moreover, these inflammatory factors enhance the overexpression of MHC-I molecules,
which could result in an increased exposure of infected cells to the immune system and
could initiate an autoimmune process that could directly contribute to islet cells damage
[173]. However an activation of MDA-5 with any other factor can not initiate autoimmunity,
whereas IFN-I-induced MDA-5 accelerated a preexistent autoimmune process in an animal
model [38].
Some studies in animals have highlighted the potent role of antibodies and immune cells
during enteroviral infection. Results on mice have shown that gammaglobulins are essential
in limiting the scope and severity of enteroviral infection by preventing viral persistence in
infected tissues [103] and T lymphocytes can deeply limit virus replication in CVB3-induced
myocarditis and pancreatitis [63].
5.1.2. Enteroviruses can induce diabetes in mice
Experiments have been conducted to evaluate the ability of CVB4 to elicit diabetes in mice.
These studies have shown that the pancreas was a predominant site of virus replication and
the target of a strong immune response.
A CVB4 strain isolated by Yoon et al. from the pancreas of a 10-year-old boy who died of
diabetic ketoacidosis and called CVB4E2, have induced hyperglycaemia with inflammation
of the Langerhans islets and β-cell necrosis when inoculated to susceptible mice SJL/J [175].
A similar result was obtain in the same SJL/J mice strain when inoculated with a CVB5
strain isolated from stools of a diabetic patient [121]. In another study, CVB4E2 has led to
hyperglycaemia and the appearance of anti-GAD antibodies in the vast majority of mice,
suggesting a potent role of enteroviruses in initiating or accelerating autoimmunity against
β-cells [57]. Diabetes with viral replication in β-cells has been also obtained when CVB4 JVB
strain was inoculated to susceptible mice [174]. In addition, diabetes has been obtained in
mice infected by CVB3 and CVB5 when animals were first treated with sub-diabetogenic
doses of streptozotocin, a highly specific β-cell toxin. Findings from that study have re‐
vealed that virus-induced diabetes can be facilitated by cumulative effects induced by genet‐
ic factors or environmental insults (chemicals, drugs, toxins), since CVB strains (B3 and B5)
used in that study ordinarily produce little if any β-cell damage [153]. Furthermore, CVB4-
induced abnormal thymic, splenic and peripheral lymphocytes repertoire maturation has
been described in mice and these lymphocyte maturation disorders have preceded the onset
of hyperglycemia in animals [22].
In a study, CD-1 mice have been infected with the diabetogenic strain CVB4E2 and followed
during one year. Results from this study have revealed a prolonged presence of viral RNA
in pancreas tissue, a significant decrease in insulin levels and islets cells destruction by two
mechanisms: directly by cytotoxic effects of IFN-γ-stimulated peritoneal macrophages and
by an antibody-dependent mechanism through islet cell autoantibody (ICA) [133]. In anoth‐
er study, infection of mice with CVB4 has led to a rapid development of the disease mediat‐
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ed by bystander activation of T cells [73], which would tend to confirm early findings that
have shown that infection of normal mice with CVB4 causes an overt diabetes associated
with low insulin levels consistent with islet cells destruction [33].
The mechanism behind this β-cell destruction has been explored in some studies. Analysis
of the results from these studies reveals that the spontaneous development of diabetes in
NOD mice can be accelerated by CVB4 infection though a “bystander” effect only if a suffi‐
cient number of pre-existing autoreactive T-cells was already present [134]. This observation
was in agreement with another study which has shown that the overexpression of a TCR
transgene specific to an islet autoantigen has induced diabetes onset 2-4 weeks after CVB4
inoculation in mice that do not develop diabetes spontaneously [73]. Islet cell destruction by
autoreactive T-cells was the result of the release of sequestered islet antigens which followed
β-cell inflammation and destruction caused by CVB infection [73, 2001]. Other studies have
stated that β-cells are phagocyted by antigen-presenting cells like macrophages, rather than
directly destroyed by a CVB-induced process [75, 133], because antigen-presenting cells iso‐
lated from CVB4-infected mice can induce diabetes if inoculated to non-infected mice [75].
Among T1D animal models, the NOD mouse remains far the most used and studied model.
The NOD mice are susceptible to spontaneous T1D that develops over several weeks and
share most aspects of human T1D [83]. In NOD mice, the disease occurs after T-cell-mediat‐
ed destruction of β-cells [87, 170]. Some studies have revealed that CVB infection effects in
NOD mice appear to be contingent upon the precise moment at which infection occurs [134,
156]. Thus, rapid T1D induction can be obtained when older NOD mice are inoculated with
CVB and the disease occurs much more rapidly when mice islets are already developing au‐
toimmune insulitis and high islet cells lytic viral replication are observed when à virulent
strain is inoculated [156]. These findings suggest that CVB replicate more readily in aged
NOD mice islet cells, especially if there is inflammation, than in those of younger animals.
Another factor seems to be the magnitude of effects of CVB4 infection onto β-cells, depend‐
ing on the permissiveness of target cells, which is closely related to their sensitivity to IFNs.
Indeed, coxsackievirus B4-infected-NOD mice which had defective IFNs responses have de‐
veloped an acute form of type 1 diabetes, similar to the one in humans following severe en‐
teroviral infection. Interferons act by inducing an antiviral state in target cells, including
pancreatic β-cells, by reducing their permissiveness to viral entry and replication. The effect
of IFNs is transmitted as an intracellular signal through the Jack-STAT signaling pathway
[140]. In transgenic NOD mice that express the suppressor of cytokine signaling 1 (SOCS-1),
a negative regulator of IFN action which inhibit the Jack-STAT signaling pathway, CVB4 in‐
fection has resulted in β-cell loss and diabetes onset. Similar results have been obtained dur‐
ing the same study in transgenic NOD mice of which β-cells were lacking IFN receptors. In
addition to inducing on β-cells a lower permissiveness to CVB4 infection, IFNs contributed
also to deeply decrease their sensitivity to NK cell-mediated destruction [50].
5.1.3. Molecular mimicry hypothesis
Glutamic acid decarboxylase 65kD (GAD65), a candidate autoantigen in the pathogenesis of
T1D, is expressed in pancreatic β-cells. Some findings from mice have shown that CTL (cyto‐
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toxic T lymphocytes) are cytotoxic to islet cells [44] and that T cell responses to GAD65 were
detectable in prediabetic NOD mice spleens prior to disease onset [89, 152]. One of the
mechanisms proposed to explain enterovirus-induced autoimmunity in T1D model is based
on the cross-reactivity between CVB antigens and β-cell endogenous proteins through mo‐
lecular mimicry. Pancreatic β-cells infection by CVB will be followed by inflammatory re‐
sponse resulting in β-cell destruction and increased self-antigen presentation due to their
phagocytosis by antigen-presenting cells (APCs). Since P2-C protein sequence of CVB parti‐
ally resembles that of human GAD65, both autoreactive and antiviral T-cells activated upon
CVB infection, might act as strong enhancers that may accelerate or aggravate the ongoing
autoimmune process [28, 151].
Regardless T-cells cross reactivity effects, experiments on CVB4-infected NOD mice have
provided the evidence that the release of β-cell antigens followed by their presentation by
APCs (antigen presentation cells) such as macrophages can initiate or promote β-cell auto‐
immunity [75].
Figure 3. Information brought by animal models regarding coxsackievirus B infection and some aspects of type 1 dia‐
betes pathogenesis
5.2. In vitro infection of β-cells and other cells with enteroviruses
Experiments have been conducted in vitro in order to analyse the hypotheses in favour of an
association between enterovirus infections and T1D. Whether enteroviruses were able to in‐
fect the pancreatic tissue is a key issue concerning the relationship between enteroviruses
and T1D. It has been shown that enteroviruses may be involved in the pathogenesis of T1D,
either through direct β-cell infection or as triggers of the autoimmune processes. In particu‐
lar, some results from in vitro experiments have suggested that enteroviruses, and especially
CVB, may infect human β-cells and the infection may result in no apparent immediate effect
or in functional impairment of β-cell [175, 174, 167, 124]. Most common enteroviruses in the
environment can infect cultured human islets with β-cell destruction [93]. The figure 4 sum‐
marizes information brought by in vitro studies regarding coxsackievirus B infection which
can be relevant for type 1 diabetes pathogenesis.
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5.2.1. Enterovirus infection of β-cells
Persistent infection of human pancreatic islets by CVB associated with alpha interferon
(IFN) synthesis was observed [23]. In this study conducted by our team, human pancreatic
islets obtained from adult brain-dead donors and cultured in noncoated membrane inserts
were infected with CVB3 and a diabetogenic (CVB4 E2) and a non-diabetogenic (CVB4 JVB)
strain of CVB4. It was displayed that both α and β cells in human pancreatic islet can be per‐
sistently infected and long term CVB replication has been observed through the presence of
infectious particles in culture supernatant fluids and intracellular viral negative-strand RNA
up to 30 days post infection. This study showed that human islets challenged with CVB can
synthesize IFN-α which is produced by infected β-cells only. These data support the hy‐
pothesis of a role of CVB in the high levels of type I IFNs that have been detected in pan‐
creas or islets of patients with T1D [51, 76]. The viral persistence accompanied by synthesis
of INF-α can enhance autoimmune processes leading to diabetes onset. The possibility that
IFN-α could take part in T1D onset in genetically predisposed host have been tested in
transgenic mice of which β-cells express this cytokine. It revealed that IFN-α was able to
provoke the onset of the disease in transgenic animals, and that neutralizing IFN-α prevent‐
ed inflammation and diabetes [142]. The expression of IFN-α in β-cells may lead to the de‐
velopment of diabetes in transgenic mice through the activation of autoimmune (islet-
reactive) CD4+ TH1 cells [20].
Recent findings have shown that type I IFNs production can be induced in CVB infected hu‐
man islet cells by intracellular viral RNA sensors such as TLR3, MDA-5 and RIG-1 genes
[77]. These pattern-recognition receptors have also been told to upregulate the synthesis and
production of chemokines. The sustaining of this process - IFNs and chemokines production
– could be deleterious and involved in the development of autoimmunity, especially since
persistent infection of islets cells in vitro by some CVB strains has been reported [23].
The infection of β-cells with CVB and the molecular pathways leading to CVB-induced β-
cell death have been investigated. One study was aimed to evaluate the effects of different
CVB4 strains on islets morphology and insulin release and another one compared inflamma‐
tory-related genes expression in CVB4-infected and uninfected isolated human islets. Re‐
sults from these studies have revealed that even though the outcome of the infection
differed, islet cells can be infected by all CVB4 strains. However, significant differences in
viral titers and cell morphology were observed according to the phenotype of the strain: one
with no cytopathic effect despite high virus titres (VD2921 stain), and the other with a pro‐
nounced cytopathic effect (V89-4557 strain), whereas a third one (JVB strain) have induced a
significant increase of insulin release [55]. A microarray analysis of RNA from CVB4-infect‐
ed human islets have shown specific induction of several inflammatory genes, some of them
encoding proteins with potent biological activity such as IL-1β, IL-6, IL-8, MCP-1 and
RANTES [117]. Recently, it has been reported that, except CVB1 and CVB3, all other CVB
viruses induced a dose-dependent production of pro-inflammatory cytokines and chemo‐
kines in a rat insulinoma β-cell line (INS-1) [107].
The release of proinflammatory cytokines may strongly contribute to maintain a local pan‐
creatic-islet inflammation that could result in an amplification of the immune attack against
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β-cells. In addition, the activation of MHC molecules in human fetal islet cells cultures in‐
fected by CVB4 could result in an increase exposure of infected cells to the immune system
and support the autoimmune response against β-cells [119].
The inflammation of β-cells is supposed to be an early event in the pathogenesis of type
1diabetes [45]. An exaggerated inflammatory response to enterovirus may contribute to in‐
duce a prolonged inflammation state and β-cell loss, and could initiate or aggravate patho‐
genic processes of type 1 diabetes.
5.2.2. Enterovirus infection of thymus
It has been shown in mouse that CVB could infect the thymus with a disruption of organ
functions that was associated with diabetes [22]. Further studies have been conducted to in‐
vestigate the mechanisms and consequences of infection of thymus with CVB. The establish‐
ment of central T-cell tolerance is ensured by the thymus. Thymic epithelial cells (TEC)
participate actively in the development of a biochemical environment needed for the matu‐
ration of immunocompetent T cells. Thymic epithelial cells are actively involved in the pro‐
motion of T-cell maturation by mediating negative and positive selection of thymocytes and
by participating to the induction of tolerance [136].
In collaboration with Pr Vincent Geenen and his team (University of Lièges, Belgium) we in‐
vestigated the hypothesis that T1D which is an autoimmune disease, can result from the dis‐
turbance of the central tolerance. Due to the role of thymus in induction and establishment of
self-tolerance, enteroviral infection of TEC may result in interference and disturbance of T-cell
ontogeny, which can induce or enhance the immune process leading to T1D. The infection of
human TEC primary cultures with CVB4 and the resulting consequences on TEC function
have been studied. Human TEC, isolated from thymus fragments obtained from children un‐
dergoing corrective surgery, were infected with CVB4 JVB and E2 strains. Findings from this
study have revealed that a cytolytic virus such as CVB4 can infect persistently human TEC cul‐
tures without obvious cytopathic effect and this infection have led to a continuous increased
production of cytokines IL-6, GM-CSF and LIF [14]. In order to evaluate the effect of enterovi‐
rus infection onto fetal thymus during pregnancy, intact explanted human foetal thymic or‐
gan  cultures  were  infected  with  CVB4E2  strain.  Results  from  this  study  have  shown
progressive  thymocyte  depletion  and  upregulation  of  MHC-I  molecules  expression  on
CD4+CD8+ double positive cells [15]. Another study was conducted on mouse to assess the ef‐
fect of CVB infection on thymocytes maturation and differentiation. In this study, whole foetal
thymus organ cultures obtained from 14 days foetal CD-1 mice were infected with CVB4E2
strain. Findings from that study have revealed in infected culture a disturbance of maturation
and differentiation of T cells characterized by increased levels of mature CD4+ and CD8+ cells
associated with decreased percentage of double positive cells [16].
Furthermore it was reported that CVB4 RNA can be found in thymus up to 70 days after per
os infection of mice with CVB4E2. In vitro, CVB4 was able to infect and replicate in primary
cultures of adult murine splenic and thymic cells [81].
The ability of enteroviruses such as CVB4 to infect the thymus during fetal life could have
deleterious effects on thymus functions, since neonatal exposure to thymotropic virus could
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induce a virus-specific nonresponsiveness [95]. A global analysis of all these findings sug‐
gests that thymus organ can be infected by coxsackievirus B which can disturb the organ
function with possible effects on the autoimmune processes leading to T1D.
5.2.3. Antibody-dependent enhancement of enterovirus infection
The antibody-dependent enhancement (ADE) of infection is a mechanism observed in vitro
with various viruses and which can intervene in pathogenic processes induced by these virus‐
es [145]. The ADE of CVB4 infection has been discovered by our group. It is caused by enhanc‐
ing antibodies devoid of neutralizing activity and has been found in serum /plasma of T1D
patients and controls. These antibodies, isolated from plasma by affinity chromatography, in‐
crease the CVB4-induced synthesis of IFN-α by human peripheral blood mononuclear cells
(PBMC) in vitro [25]. It has been demonstrated that IFN-α synthesis by PBMC infected with
CVB4 prealably incubated with specific antibodies is a result of the infection of monocytes that
occurs by a mechanism involving the receptors CAR and those for the Fc portion of IgG mole‐
cule, FcγRII (Fcγ receptor II) and FcγRIII localised at the cell surface membrane [66]. CVB4 can
strongly induce the production of IFN-α by PBMCs from patients with T1D compared with
PBMC from healthy controls, which is due to anti-CVB4 enhancing antibodies bound to the cell
surface membrane. In addition, a higher level of IFN-α was produced by PBMC of patients in‐
oculated with CVB4 prealably incubated with plasma of patients [67]. The target of these anti‐
bodies has been identified as the enteroviral protein VP4 and it has been shown that the
prevalence and the titres of anti-VP4 antibodies were higher in patients with T1D than in con‐
trol subjects [26]. Specific anti-VP4 antibodies enhance the infection of PBMC with CVB4 [129].
The sequence of VP4 recognized by these antibodies was investigated and identified in com‐
petition experiments as amino acids 11 to 30 by using synthetic overlapping peptides span‐
ning CVB4E2 VP4 protein [130]. The VP4 protein and a VP4 peptide have been used to detect
anti-CVB4 enhancing antibodies by ELISA [26, 130]. The fact that enhancing anti-CVB4 anti‐
bodies bind the viral particles through VP4 is challenging, since, according the structural anal‐
ysis of frozen enteroviruses by X-ray diffraction, the capsid protein VP4 is localized along the
inner virion surface, like the amino-terminal sequences of the three external proteins VP1, VP2
and VP3. The explanation lies in the dynamic character of the virus structure at 37°C that
would allow an exposure of these normally internal sequences and making a piece of the VP4
protein accessible to antibodies, as it has been shown in the case of the amino-terminal part of
VP1 in the poliovirus system [96].
The increased infection of monocytes with CVB4 due to enhancing antibodies could lead, in
vivo, in dissemination and worsening of histological lesions that may contribute to CVB4-
induced disease, as described in a model of CVB3-induced myocarditis [131, 58, 92]. Further‐
more, the enterovirus –induced production of IFN-α enhanced by antibodies, can play a
pathogenic role. Indeed, chronic IFN-α synthesis or its abnormal activation in response to
recurrent or repeated enteroviral infections can be associated with disorders leading to auto‐
immune diseases [23].
Further studies are needed to investigate the role of enhancing antibodies in the CVB-in‐
duced pathogenesis of T1D.
Viruses and Type 1 Diabetes: Focus on the Enteroviruses
http://dx.doi.org/10.5772/52087
53
Figure 4. Information brought by in vitro studies regarding coxsackievirus B infection
5.3. Complex relationship between enteroviruses and type 1 diabetes
As mentioned above, the role of enteroviruses in T1D disease is strongly suspected. In con‐
trast, a protective role of enteroviruses is suggested as well. Experimental data in favour of a
protective role of these viruses have been reported. Indeed, some studies have shown that,
rather than triggering an autoimmune process, CVB infections can provide significant pro‐
tection against the development of T1D [155, 48]. Coxsackievirus B4, the human enterovirus
most associated with an etiologic role in human T1D, has been reported to increase the rate
of diabetes onset in older NOD mice but not in younger mice [134]. This result has been con‐
firmed by other groups who provided evidence that disease induction required a pre-exist‐
ing accumulation of β-cell specific autoreactive T cells within the pancreas, a phenomenon
observed in older NOD mice, but not in younger mice [74, 156]. This protective effect may
involve the virus strain, its virulence and replication rate, as well as the stage of autoim‐
mune development, and the mechanism relies in long-term tolerance due to an increase in
protective regulatory T cells with TGF-β production [49].
These findings support the concept that virus infections occurring early in childhood had a
protective effect against T1D and are in agreement with the hygiene hypothesis [7, 157]. In‐
deed, it should be emphasized that there are significantly more enterovirus infections annu‐
ally than new cases of T1D in population. The decreased enterovirus exposure rates
following the increased hygiene levels might explain the high risk of developing the disease,
since it has been revealed in epidemiological studies that T1D incidence is higher in devel‐
oped countries than in developing ones, from less than 1 per 100,000 inhabitants in Asia to
14 in US and even more than 30 per 100,000 in Scandinavia [139].
6. Conclusion
Type 1 diabetes is a complex multifactorial disease. The involvement of enteroviruses as a
major non-genetic etiological factor is a topic of reflexion for several research teams world‐
wide. Studies from these teams have shown that enteroviral infections, especially coxsackie‐
virus B infections, are closely linked with T1D. Findings from experimental in vitro and in
vivo studies have lightened the potent role that can play enteroviruses in inducing and/or
worsening the disease. However, in certain particular conditions, enteroviruses can induce a
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protective effect in mouse model. Therefore, further studies are needed to understand the
mechanisms behind this complex relationship between enteroviruses and T1D.
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